Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 77

1.

Risk factors for neutropenia and febrile neutropenia following prophylactic pegfilgrastim.

Lee M, Yee J, Kim JY, Kim JY, An SH, Lee KE, Gwak HS.

Asia Pac J Clin Oncol. 2019 Aug;15(4):231-237. doi: 10.1111/ajco.13152. Epub 2019 Apr 17.

PMID:
30997742
2.
3.

LA-EP2006: A Pegfilgrastim Biosimilar.

Hoy SM.

BioDrugs. 2019 Apr;33(2):229-232. doi: 10.1007/s40259-019-00348-3. Review.

PMID:
30887256
4.

Safety analysis of proposed pegfilgrastim biosimilar in Phase I and Phase III studies.

Harbeck N, Wang J, Otto GP, Gattu S, Krendyukov A.

Future Oncol. 2019 Apr;15(12):1313-1322. doi: 10.2217/fon-2018-0878. Epub 2019 Mar 5.

5.

Chemotherapy-induced neutropenia/febrile neutropenia prophylaxis with biosimilar filgrastim in solid tumors versus hematological malignancies: MONITOR-GCSF study.

Ludwig H, Bokemeyer C, Aapro M, Boccadoro M, Gascón P, Denhaerynck K, Krendyukov A, Abraham I, MacDonald K.

Future Oncol. 2019 Mar;15(8):897-907. doi: 10.2217/fon-2018-0814. Epub 2019 Mar 4.

6.

Randomized phase 3 efficacy and safety trial of proposed pegfilgrastim biosimilar MYL-1401H in the prophylactic treatment of chemotherapy-induced neutropenia.

Waller CF, Ranganna GM, Pennella EJ, Blakeley C, Bronchud MH, Mattano LA Jr, Berzoy O, Voitko N, Shparyk Y, Lytvyn I, Rusyn A, Popov V, Láng I, Beckmann K, Sharma R, Baczkowski M, Kothekar M, Barve A.

Ann Hematol. 2019 May;98(5):1217-1224. doi: 10.1007/s00277-019-03639-5. Epub 2019 Mar 1.

7.
8.

[A Case of Arteritis That Developed after Pegfilgrastim Administration during Chemotherapy for Breast Cancer].

Chino T, Oba T, Yamamoto K, Takekoshi D, Iesato A, Ito T, Kanai T, Maeno K, Ito K.

Gan To Kagaku Ryoho. 2018 Dec;45(12):1771-1774. Japanese.

PMID:
30587739
9.

Real-world safety experience of tevagrastim/ratiograstim/biograstim and tbo-filgrastim, short-acting recombinant human granulocyte colony-stimulating factors.

Abboud CN, Lang N, Fung H, Lammerich A, Buchner A, Liu P, Mueller U, Pettengell R, Diel IJ, Link H, Pathak A.

Support Care Cancer. 2019 Jul;27(7):2569-2577. doi: 10.1007/s00520-018-4522-5. Epub 2018 Nov 15.

PMID:
30443809
10.

Severe thrombocytopenia related to filgrastim mobilization in a healthy donor.

Iltar U, Salim O, Küpesiz A.

Transfus Apher Sci. 2018 Dec;57(6):777-778. doi: 10.1016/j.transci.2018.10.002. Epub 2018 Oct 6. No abstract available.

PMID:
30340938
11.

First Pegfilgrastim Biosimilar Approved.

Aschenbrenner DS.

Am J Nurs. 2018 Oct;118(10):19-20. doi: 10.1097/01.NAJ.0000546389.75712.6e. No abstract available.

PMID:
30260881
12.

Comparison of biosimilar filgrastim with a reference product: pharmacokinetics, pharmacodynamics, and safety profiles in healthy volunteers.

Choi C, Yoo BW, Kim CO, Hong T, Jin BH, Seo KS, Jang JY, Park MS.

Drug Des Devel Ther. 2018 Aug 1;12:2381-2387. doi: 10.2147/DDDT.S158277. eCollection 2018.

13.

Risk of chemotherapy-induced febrile neutropenia with same-day versus next-day pegfilgrastim prophylaxis among patients aged ≥65 years: a retrospective evaluation using Medicare claims.

Weycker D, Hanau A, Lonshteyn A, Bowers C, Bensink M, Garawin T, Chandler D.

Curr Med Res Opin. 2018 Sep;34(9):1705-1711. doi: 10.1080/03007995.2018.1495621. Epub 2018 Jul 25.

PMID:
29962268
14.

Pharmacokinetic and pharmacodynamic bioequivalence study of a pegfilgrastim biosimilar INTP5 in healthy subjects.

Singh I, Patel A, Patel R, Jose V.

Cancer Chemother Pharmacol. 2018 Aug;82(2):329-337. doi: 10.1007/s00280-018-3620-x. Epub 2018 Jun 15.

PMID:
29948023
15.

Effectiveness and Safety of Pegfilgrastim in BEP Treatment for Patients with Germ Cell Tumor.

Iwamoto H, Izumi K, Natsagdorj A, Makino T, Nohara T, Shigehara K, Kadono Y, Mizokami A.

In Vivo. 2018 Jul-Aug;32(4):899-903. doi: 10.21873/invivo.11326.

16.

Reduced dose pegfilgrastim is associated with less bone pain without increased neutropenia: a retrospective study.

Lower EE, Charif M, Bartelt M.

Cancer Chemother Pharmacol. 2018 Jul;82(1):165-170. doi: 10.1007/s00280-018-3607-7. Epub 2018 Jun 5.

PMID:
29869680
17.

Clinical Outcomes of Treatment with Filgrastim Versus a Filgrastim Biosimilar and Febrile Neutropenia-Associated Costs Among Patients with Nonmyeloid Cancer Undergoing Chemotherapy.

Schwartzberg LS, Lal LS, Balu S, Campbell K, Brekke L, DeLeon A, Elliott C, Korrer S.

J Manag Care Spec Pharm. 2018 Oct;24(10):976-984. doi: 10.18553/jmcp.2018.17447. Epub 2018 Apr 24.

18.

A pharmacokinetics and pharmacodynamics equivalence trial of the proposed pegfilgrastim biosimilar, MYL-1401H, versus reference pegfilgrastim.

Waller CF, Tiessen RG, Lawrence TE, Shaw A, Liu MS, Sharma R, Baczkowski M, Kothekar MA, Micales CE, Barve A, Ranganna GM, Pennella EJ.

J Cancer Res Clin Oncol. 2018 Jun;144(6):1087-1095. doi: 10.1007/s00432-018-2643-3. Epub 2018 Apr 18.

PMID:
29671069
19.

The incidence and timing of leukocyte overshoot after pegfilgrastim administration.

Usami E, Kimura M, Iwai M, Go M, Asano H, Takenaka S, Adachi S, Yoshimura T.

J Oncol Pharm Pract. 2019 Jun;25(4):869-874. doi: 10.1177/1078155218769140. Epub 2018 Apr 13.

PMID:
29651919
20.

An open-label, dose-ranging study of Rolontis, a novel long-acting myeloid growth factor, in breast cancer.

Vacirca JL, Chan A, Mezei K, Adoo CS, Pápai Z, McGregor K, Okera M, Horváth Z, Landherr L, Hanslik J, Hager SJ, Ibrahim EN, Rostom M, Bhat G, Choi MR, Reddy G, Tedesco KL, Agajanian R, Láng I, Schwartzberg LS.

Cancer Med. 2018 May;7(5):1660-1669. doi: 10.1002/cam4.1388. Epub 2018 Mar 23.

Supplemental Content

Loading ...
Support Center